# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Joanna Gajuk maintains Enhabit (NYSE:EHAB) with a Underperform and lowers the price target from $9...
Enhabit, Inc. (NYSE:EHAB) ("Enhabit" or the "Company"), a leading home health and hospice provider, today annou...
The Company is filing a preliminary proxy statement because AREX Capital Management, LP has notified the Company that it intend...
Leerink Partners analyst Whit Mayo upgrades Enhabit (NYSE:EHAB) from Underperform to Market Perform and announces $8.5 price...
Jefferies analyst Brian Tanquilut downgrades Enhabit (NYSE:EHAB) from Buy to Hold and lowers the price target from $14 to $8...
Believes Enhabit's Shares Do Not Reflect its Intrinsic Value or Strategic Potential Has Nominated Seven Highly Qualified In...
GUIDANCEThe Company reaffirmed its full-year 2024 guidance as follows: ($ in millions, except per share data)2024 Guidance Net...